Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Promyelocytic, Acute 4Leukemia 3Neoplasms, Plasma Cell 2Multiple Myeloma 2Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Hematologic Diseases 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Azacitidine 2ruxolitinib 1posaconazole 1CPI-0610 1Arsenic Trioxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Myelodysplastic-Myeloproliferative Diseases × Arsenic Trioxide × Clear all
NCT00020969 2020-10-05

Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

CTI BioPharma

Phase 2 Terminated
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡